Management of Secondary Hyperparathyroidism in Chronic Renal Failure

Contraindications and Concerns

Patients with chronic renal failure (CRF) have disturbed calcium and phosphorus metabolism, with secondary hyperparathyroidism being a common complication that requires careful management, as noted by the American Journal of Kidney Diseases 1, 2

Management of bone disease in CRF focuses on controlling phosphorus levels, maintaining normal calcium levels, and preventing excessive PTH secretion, according to the American Journal of Kidney Diseases 2, 4
Bone biopsy may be necessary to accurately diagnose the type of renal osteodystrophy present, such as hyperparathyroid bone disease, adynamic bone disease, osteomalacia, or mixed uremic osteodystrophy, as recommended by the American Journal of Kidney Diseases 1
PTH levels between 100-500 pg/mL in CRF patients may not reliably predict the underlying bone disease, making treatment decisions challenging, as reported by the American Journal of Kidney Diseases 1

For CRF patients with elevated PTH levels, the standard approach includes phosphate binders to control serum phosphorus levels, as recommended by the American Journal of Kidney Diseases 2, 4
Vitamin D sterols (calcitriol or analogs) are used to suppress PTH secretion, according to the American Journal of Kidney Diseases 2, 4
Calcimimetics are used for persistent secondary hyperparathyroidism, as noted by Nature Reviews Nephrology and PLoS Medicine 5, 6
Parathyroidectomy is considered for severe, refractory cases, as recommended by Nature Reviews Nephrology and the American Journal of Kidney Diseases 1, 5
Careful monitoring of calcium, phosphorus, and PTH levels is essential during treatment, as emphasized by the American Journal of Kidney Diseases 2